Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Insmed (NASDAQ:INSM) had its price target lifted by investment analysts at Wells Fargo & Company from $85.00 to $107.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 31.51% from the company’s current price.

INSM has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, February 7th. JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Finally, Stifel Nicolaus increased their price target on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.86.

Insmed Trading Up 2.6 %

Shares of NASDAQ INSM opened at $81.36 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $14.56 billion, a P/E ratio of -14.66 and a beta of 1.11. Insmed has a 1-year low of $21.92 and a 1-year high of $82.04. The business has a fifty day moving average price of $73.51 and a 200 day moving average price of $73.31.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martina M.D. Flammer sold 6,172 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the sale, the insider now directly owns 101,549 shares in the company, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 495,135 shares of company stock worth $38,409,713 over the last three months. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in Insmed during the fourth quarter worth about $259,000. Fourth Dimension Wealth LLC acquired a new stake in Insmed during the fourth quarter worth about $278,000. Vise Technologies Inc. grew its holdings in Insmed by 6.3% during the fourth quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 336 shares during the period. Castleark Management LLC grew its holdings in Insmed by 21.9% during the fourth quarter. Castleark Management LLC now owns 52,780 shares of the biopharmaceutical company’s stock worth $3,644,000 after acquiring an additional 9,480 shares during the period. Finally, Elequin Capital LP acquired a new stake in Insmed in the fourth quarter valued at approximately $28,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.